WW International Inc. Common Stock (WW)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a balance sheet that can survive mistakes. WW does not clear that bar today. The company sells weight-management programs and digital subscriptions, but annual revenue has slipped from $1.0B in fiscal year 2022 to $889.6M in fiscal year 2023 and $785.9M in fiscal year 2024. It lost $256.9M in fiscal year 2022, $112.3M in fiscal year 2023, and $345.7M in fiscal year 2024, with fiscal year 2024 diluted EPS of -$4.34. The latest reported quarter, fiscal Q2 2026, the quarter ended 2026-06-30, was profitable—revenue $162.3M and net income $14.1M—but that follows a $52.0M net loss in fiscal Q1 2026, the quarter ended 2026-03-31, and a $56.3M net loss in fiscal Q3 2025, the quarter ended 2025-09-30. That is not steady earning power. Free cash flow is negative: trailing FCF was -$26.8M, a -17.8% FCF yield on the $151M market cap, per FairStock calculations. Debt to equity is 1.53, ROE is -30.71%, and the Altman Z-Score of 0.30 signals real financial distress. On price, the close on 2026-10-13 was $15.10. FairStock puts P/E at 1.58, P/B at 0.47, EV/EBITDA at 5.50, and the Graham Number at $77.30, an 80.47% margin of safety. Those are statistically cheap, but the cheapness rests on unstable earnings and a leveraged balance sheet. Piotroski is 7/9, and the Lynch category is TURNAROUND—loss in the latest year after earlier profits. A true turnaround could reward patient investors, but I see no durable moat and would require evidence of sustained positive free cash flow and debt reduction before calling this a Graham-style bargain.

In plain English: WW International sells weight-loss and wellness programs, digital subscriptions, and support for people using new weight-loss medicines or managing diabetes and menopause. The business looks weak because sales are shrinking, recent full-year results showed losses, and it is using more cash than it brings in. The stock price looks inexpensive compared with the company’s net assets, but the low price reflects serious worries about debt and whether the turnaround will last.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-24) · FY2024 10-K (period ended 2024-12-28) · FY2023 10-K (period ended 2023-12-30) · FY2022 10-K (period ended 2022-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer